10-Q: Pharma-Bio Serv Narrows Q3 Loss, Boosts Margins

Pharma-Bio Serv, Inc. reported a significantly reduced net loss for the nine months ended July 31, 2025, driven by improved gross profit margins and reduced operating expenses, despite a slight revenue decline.

Summary

• Pharma-Bio Serv reported a net loss of $(100,361) for the nine months ended July 31, 2025, a significant improvement from $(793,730) in the prior year period.
• Revenues for the nine-month period decreased by 4.5% to $6.85 million, primarily due to declines in Puerto Rico, US, and Brazil consulting markets, partially offset by a $1.0 million increase in European project revenue.
• Gross profit margin for the nine months increased by 6.6 percentage points to 31.5%, driven by improved margins in Puerto Rico and US, and a high-margin European project.
• Selling, general, and administrative expenses decreased by $0.3 million for the nine-month period, contributing to the reduced net loss.
• The company maintains $11.5 million in working capital as of July 31, 2025, and repurchased 37,701 shares of common stock during the nine-month period.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvements in net loss and gross profit margins, indicating better operational efficiency. However, overall revenue decline, uncertainty regarding a key tax grant, and an uncollected legal judgment temper the positive sentiment.

Positives

• Net loss for the nine months ended July 31, 2025, significantly improved to $(100,361) from $(793,730) in the prior year, an earnings increase of approximately $0.7 million.
• Basic and diluted loss per common share for the nine months improved to $(0.004) from $(0.035) in the prior year.
• Gross profit margin for the nine months ended July 31, 2025, increased by 6.6 percentage points to 31.5% (from 24.9% in 2024), primarily due to improved margins in Puerto Rico and United States consulting markets and a high-margin European project.
• Selling, general, and administrative expenses decreased by $0.3 million for the nine months ended July 31, 2025, reflecting planned savings.
• European consulting market revenue increased by approximately $1.0 million for the nine months ended July 31, 2025.
• Net cash used in operating activities improved to $(494,552) for the nine months ended July 31, 2025, from $(645,126) in the prior year.
• The company maintains a strong working capital position of approximately $11.5 million as of July 31, 2025.
• The company repurchased 37,701 shares of its common stock during the nine-month period ended July 31, 2025, under its ongoing repurchase program.

Negatives

• Total revenues for the nine months ended July 31, 2025, decreased by approximately $0.3 million (4.5%) to $6.85 million compared to the same period last year.
• Project revenue declined in the Puerto Rico, US, and Brazil consulting markets by approximately $0.8 million, $0.4 million, and $0.1 million, respectively, for the nine months ended July 31, 2025.
• Cash and cash equivalents decreased by $2,809,604 from October 31, 2024, to July 31, 2025, primarily due to cash dividends paid and net cash used in operating and investing activities.
• Total assets decreased by $2,706,652 from October 31, 2024, to July 31, 2025.
• Total stockholders' equity decreased by $1,788,643 from October 31, 2024, to July 31, 2025, partly due to the cash dividend payment of $1,719,918.

Risks

• Uncertainty regarding the outcome of the renegotiation application for the Puerto Rico Industrial Tax Exemption Grant (PRIDCO), which expired on October 31, 2024.
• Exposure to regional or global conflicts, including war or economic sanctions between nations.
• Impact of price inflation on operations and profitability.
• Potential adverse effects from pandemics and operational constraints imposed by customers due to pandemics.
• Challenges from changes in tax laws, specifically the Tax Cuts and Jobs Act of 2017 (TCJA) and the recently enacted One Big Beautiful Bill Act of 2025 (OBBBA), which increases the effective tax rate on net CFC tested income from 10.5% to approximately 12.6% starting fiscal year ended October 31, 2027.
• Adverse effects from bio-pharmaceutical industry consolidations.
• Trends in managing contract resources by customers.
• Inability to guarantee a successful outcome in collecting the $6,717,431.69 judgment against Romark Global Pharma, LLC and its affiliates, as assets have not yet been identified.

Future Outlook

Management believes that future profitability and liquidity will be dependent on the effect of local and global economic conditions, including any impacts of regional or global conflicts, price inflation, pandemics, changes in tax laws (such as TCJA and OBBBA), worldwide life science manufacturing industry consolidations, operational constraints imposed by customers due to pandemics, and resource management trends. The company also faces uncertainty regarding the outcome of its renegotiation application for the Puerto Rico Industrial Tax Exemption Grant.

Management Comments

• Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months.

Industry Context

Pharma-Bio Serv operates in the compliance and technology transfer services consulting sector, primarily serving the pharmaceutical, chemical, biotechnology, medical devices, cosmetics, and food industries. The market is competitive, with local, US-dedicated, and large engineering and consulting firms. The industry is subject to trends such as consolidations and evolving resource management practices by clients, which can impact the company's performance.

Legal Proceedings

• Pharma-Bio Serv PR, Inc., Pharma Serv, Inc., and Scienza Labs, Inc. filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC and Romark Holdings, LLC on March 15, 2023.
• A judgment was entered on November 13, 2023, ordering Romark to pay jointly $6,717,431.69, including a principal amount of $5,246,782, plus interest.
• Collection efforts are ongoing, but the company has been unable to identify assets of Romark against which to collect, and cannot guarantee a successful outcome.

Stakeholder Impact

• Shareholders: Experienced a reduced net loss and continued cash dividends ($0.075 per share), alongside ongoing share repurchases (37,701 shares in nine months). However, the uncertainty surrounding the PRIDCO tax grant and the uncollected Romark judgment pose potential risks to future value.
• Employees: The company continues to operate in its consulting services, implying stable employment for its consulting team of engineers and life science professionals.
• Customers: Continued provision of technical compliance consulting services to the pharmaceutical, chemical, medical device, biotechnology, cosmetics, and food industries across Puerto Rico, the United States, and Europe.
• Creditors: The company maintains a strong working capital position of $11.5 million, suggesting a healthy ability to meet short-term obligations.

Next Steps

• Continue collection efforts against Romark Global Pharma, LLC and its affiliates for the $6,717,431.69 judgment.
• Await a status update from PRIDCO regarding the renegotiation application for the Puerto Rico Industrial Tax Exemption Grant.
• Assess the impact of the One Big Beautiful Bill Act of 2025 (OBBBA) on consolidated financial statements, effective fiscal year ended October 31, 2027.

Key Dates

Recommendation

While Pharma-Bio Serv demonstrated significant improvements in net loss and gross profit margins, the overall revenue decline and the uncertainty surrounding the collection of a substantial legal judgment against Romark, coupled with the pending renegotiation of a critical Puerto Rico tax grant, suggest a 'hold' position. The company's strong working capital and ongoing stock repurchase program are positive, but these are balanced by the operational challenges and tax policy changes.

Keywords

Pharma-Bio Serv, consulting, pharmaceutical, biotechnology, medical devices, FDA compliance, regulatory, Puerto Rico, United States, Europe, 10-Q, financial results, Q3 2025